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Tolerance to the antinociceptive effect of mu-opioid receptor (MOPr) agonists, such as 
morphine and fentanyl, greatly limits their effectiveness for long-term use to treat pain. 
Clinical studies have shown that combination therapy and opioid rotation can be used to 
enhance opioid-induced antinociception once tolerance has developed. The mechanism 
and brain regions involved in these processes are unknown. The purpose of this study 
was to evaluate the contribution of the ventrolateral periaqueductal gray (vlPAG) to 
antinociceptive tolerance and cross-tolerance between administration and co-
administration of morphine and fentanyl. Tolerance was induced by pretreating rats with 
morphine or fentanyl or low-dose combination of morphine and fentanyl into the vlPAG 
followed by assessment of cross-tolerance to the other opioid. In addition, tolerance to 
the combined treatment was assessed. Cross-tolerance did not develop between 
repeated vlPAG microinjections of morphine and fentanyl. Likewise, there was no 
evidence of cross-tolerance from morphine or fentanyl to co-administration of morphine 
and fentanyl. Co-administration did not cause cross-tolerance to fentanyl. Cross-
tolerance was only evident to morphine or morphine and fentanyl combined in rats 
pretreated with co-administration of low-doses of morphine and fentanyl. In conclusion, 
cross-tolerance does not develop between morphine and fentanyl within the vlPAG. 
This finding is consistent with the functionally selective signaling that has been reported 
for antinociception and tolerance following morphine and fentanyl binding to the MOPr. 
This research supports the notion that combination therapy and opioid rotation may be 
useful clinical practices to reduce opioid tolerance and other side effects.  
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Perspective: This preclinical study shows that there is a reduction in cross tolerance 
between morphine and fentanyl within the periaqueductal gray which is key brain region 
in opioid antinociception and tolerance.  
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HIGHLIGHTS 
• The periaqueductal gray is site of action for reduced opioid cross-tolerance 
• Co-administration of low-dose opioids can enhance antinociception 






Morphine and fentanyl are two of the most commonly used drugs to treat pain. 
Chronic use is limited by unpleasant side effects and the development of tolerance. 
Opioid rotation and co-administration have been used to enhance pain relief and limit 
these side effects 28, 44. Although animal studies report additive antinociceptive effects 
when morphine and fentanyl are co-administered 5, 39, clinical research indicates that 
the analgesic efficacy of co-administered morphine and fentanyl is greater than 
administration of either opioid alone 28, 47. This effect appears to be the result of 
maintained fentanyl potency despite the development of tolerance to morphine 42.  
Many preclinical studies evaluating cross-tolerance between morphine and 
fentanyl show enhanced antinociception and reduced tolerance when one opioid is 
substituted for the other 10, 35, 36, 43. Other studies show cross-tolerance with as little as a 
single injection, as well as with continuous administration 26, 40. Route and length of 
administration may be key factors in the analgesic efficacy of co-administered opioids.  
Opioids produce antinociception by binding to mu-opioid receptors at sites 
throughout the nervous system. Microinjection of either morphine or fentanyl into the 
ventrolateral periaqueductal gray (vlPAG) produces antinociception 3 and repeated 
administration of either drug results in tolerance to this antinociception 1.  Despite these 
similarities, the intracellular signaling molecules appear to be distinct. Tolerance to 
repeated morphine injections into the vlPAG is mediated by C-Jun N –terminal kinase 
(JNK), whereas tolerance to repeated fentanyl microinjections is mediated by G protein–
coupled receptor kinase (GRK) 32. This difference suggests that within the vlPAG there 
should be no cross-tolerance between morphine and fentanyl microinjections. This 
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hypothesis will be tested by microinjecting rats with morphine, fentanyl, or a 







Experiments were performed on male Sprague-Dawley rats (n = 93) with a mean 
weight of 277g (230 – 330g). Prior to surgery rats were double housed on a 12-hour 
light-dark cycle (lights on at 7AM). Food and water were available at all times except 
during testing. All procedures were approved by the Washington State University 
Animal Care and Use Committee and conducted in accordance with the guidelines for 
animal use described by the International Association for the Study of Pain. 
 
Stereotaxic Surgery and Microinjections 
Rats were anesthetized with pentobarbital (60 mg/kg, i.p.) and implanted 
unilaterally with a guide cannula (23 gauge; 9 mm long) aimed at the vlPAG using 
stereotaxic techniques (AP:  +1.7 mm, ML: ±0.6 mm, DV: -4.6 mm from lambda). 
Following surgery, the guide cannula was occluded with a 9 mm stylet. Rats were 
handled daily following surgery. Morphine sulfate (a gift from the National Institute on 
Drug Abuse) and fentanyl citrate (Sigma-Aldrich), were dissolved in sterile saline. Drugs 
were administered through a 31-gauge injection cannula inserted into and extending 2 
mm beyond the guide cannula. One day prior to testing, the injector was inserted into 
the guide cannula without drug administration to habituate them to the procedure and 






Behavioral testing  
Nociception was assessed using the hot plate test in which the latency for the rat to 
lick the hind paw was measured when placed on a 52.5°C hotplate. The rat was 
removed if no response occurred within 50 s. Rats with a baseline hot plate latency 
greater than 25 s were not included in data analysis. Rats were randomly assigned and 
injected into the vlPAG with either 0.9% saline (0.4 μL), morphine (5 μg/0.4 μL), fentanyl 
(3 μg/0.4 μL), or a morphine/fentanyl combination (2.5 μg of morphine and 1.5 μg of 
fentanyl in 0.4 µl). These combination doses were chosen as half the ED50 dose for 
each opioid so as to result in an equiantinociceptive dose compared to each opioid 
alone. Nociception was assessed in a subset of rats at 5, 30, & 60 minutes after the first 
injection to determine optimal test time in tolerance experiments. Tolerance was 
established by repeated injections of either drug alone or the combination twice a day 
for two days 1. Nociceptive testing was only conducted following the first and the last 
injections to prevent the development of behavioral tolerance 19. Only male rats were 
used given that tolerance mediated by PAG is minimal in female rats 20. 
The presence of tolerance was assessed on Day 3 using a cumulative dosing 
procedure 31. Increasing third log doses of morphine (cumulative doses of 1, 2.2, 4.6, 
10, 22 μg/0.4 μL), fentanyl (cumulative doses of 0.46, 1, 2.2, 4.6 & 10 μg/0.4 μL), or a 
combination of morphine (0.5, 1.1, 2.3, 5, & 11 μg/0.4 μL) and fentanyl (0.23, 0.5, 1.1, 
2.3, & 5 μg/0.4 μL) was microinjected into the vlPAG. Half of the cumulative dose of 
morphine and fentanyl was used at each step when co-administered. The timing for 
cumulative dosing for morphine and fentanyl alone have been established previously 3, 
31 as follows morphine was injected at 20 min intervals followed by hot plate testing 15 
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min after each injection. Fentanyl was injected at 4 min intervals with behavioral testing 
2 min after each injection.  Co-administered of morphine and fentanyl was injected at 7 
min intervals to capture peak antinociception of the combination within the time course 
of both drugs (see Fig. 2). Rats were tested on the hot plate 5 min after each injection. 
Tolerance was defined as a significant rightward shift in the dose response curve by 
comparing ED50 values for rats pretreated with an opioid vs. the saline vehicle.  
 
Histology and data analysis  
Following testing, rats received a lethal dose of Halothane. Brains were removed 
and stored in formalin (10%). At least 2 days later the brain was sliced coronally (100 
μm) to determine the location of the injection site 37. Only those injections in or 
bordering the vlPAG were included in data analysis (Figure 1). Dose-response curves 
were plotted using GraphPad (Prism 6) and the half maximal antinociceptive effect 
(ED50) was calculated for each group 1. ANOVAs were used to determine statistically 
significant differences between groups (α < 0.05). Data are presented as mean ± SEM 
unless otherwise stated. A Bonferroni post-hoc analysis was used when necessary to 






Opioid-induced antinociception in vlPAG 
A subset of rats used in each of the tolerance experiments were tested before and 
5, 30, and 60 minutes after opioid administration to determine the time course for 
antinociception to co-administration of morphine and fentanyl. There were no significant 
differences in baseline hot plate latencies between groups prior to drug administration 
(F(3, 28) = 2.24 p = 0.11). Microinjection of morphine (5 μg/0.4 μL), fentanyl (3 μg/0.4 μL), 
and combined morphine/fentanyl (2.5 μg & 1.5 μg/0.4 μL) into the vlPAG caused a 
significant increase in hot plate latency compared to saline controls (Figure 2; F(3, 143) = 
22.97; p < 0.05). Administration of morphine and combined morphine/fentanyl produced 
antinociception at 5, 30, and 90 min post injection compared to saline controls. 
Microinjection of fentanyl alone had a rapid onset and offset, producing a significant 
increase in hot plate latency compared to saline only at the 5 min time point (Bonferroni; 
p < 0.05).  
 
Lack of cross-tolerance between morphine and fentanyl in vlPAG 
Repeated microinjections of fentanyl twice daily for 2 days did not cause a 
significant change in morphine potency on Day 3 compared to saline treated controls 
(Figure 3a; F(1, 76) = 1.66; p = 0.20). Morphine potency was 4.2 ± 1.04 µg (N = 8) and 3.2 
± 0.96 µg (N = 8) following pretreatment with fentanyl or saline, respectively. Similarly, 
pretreatment with morphine did not cause a significant change in fentanyl potency 
(Figure 3b; F(1, 71) = 1.93, p = 0.17). Fentanyl potency was 1.7 ± 0.67 µg (N = 7) and 2.4 
± 0.57 µg (N = 8) following pretreatment with morphine or saline, respectively. The lack 
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of cross-tolerance between morphine and fentanyl is consistent with previous studies 
showing distinct intracellular mechanisms for tolerance to morphine and fentanyl 
antinociception 26, 32.  
 
Co-administration of morphine and fentanyl 
Co-administration of morphine and fentanyl for two days caused cross-tolerance to 
morphine, but not fentanyl antinociception. Pretreatment with morphine and fentanyl 
caused a significant rightward shift in the morphine dose-response curve compared to 
rats pretreated with saline (Figure 4a; F(1, 66) = 6.96; p < 0.05). Morphine ED50 was 12.5 
± 3.69 µg in rats pretreated with co-administered morphine/fentanyl compared to 6.2 ± 
2.35 µg in rats pretreated with saline. In contrast, co-administration of morphine and 
fentanyl did not alter the fentanyl dose-response curve (Figure 4b). There was no 
significant difference in the antinociceptive potency of fentanyl (3.7 ± 0.52 vs. 3.9 ± 
0.73) in rats pretreated with co-administered morphine/fentanyl or saline, respectively 
(F(1, 76) = 0.14; p = 0.70).   
Cross-tolerance was not evident when the experiment was conducted in the 
opposite direction. That is, pretreatment with morphine or fentanyl for two days did not 
cause a shift in the combined morphine/fentanyl dose-response curve (Figure 5a; F(2, 
114) = 1.03; p = 0.36). Pretreatment with morphine or fentanyl alone caused log shifts to 
co-administered morphine/fentanyl of only 0.07 and -1.0, respectively. However, 
combined pretreatment with morphine and fentanyl caused a rightward shift in the 
combined dose-response curve on Day 3 (Figure 5b; F(1, 76) = 9.91; p < 0.05). This 
tolerance was evident by a full one-third log shift in the combined morphine/fentanyl 
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ED50. This was the largest rightward shift in the dose response curve for any of the 





The current study found that cross-tolerance did not develop between morphine 
and fentanyl when microinjected into the vlPAG using the same paradigm that produces 
tolerance to each drug alone 1, 31, 45. In addition, rats treated with either opioid alone did 
not show tolerance to the co-administration of morphine and fentanyl. Only two 
conditions resulted in antinociceptive tolerance; pretreatment with low dose combination 
of both opioids followed by testing with the same combination or with morphine alone 
(Table 1).  
A lack of cross-tolerance between morphine and fentanyl has also been reported 
following systemic administration 10, 35, 36, 43. The clinical use of fentanyl to treat 
breakthrough pain in patients undergoing chronic opioid treatment also suggests a lack 
of cross-tolerance between fentanyl and other opioids 9, 18, 33. Co-administration of 
fentanyl is frequently used to reestablish pain relief when tolerance has developed to a 
particular opioid 27, 47.  In addition to enhancing analgesia, co-administration of opioids 
has been reported to reduce side effects such as nausea, vomiting, and sedation 24, 28, 
38, 41.  
The lack of cross-tolerance between morphine and fentanyl suggests that these two 
opioids act at different sites and/or via different mechanisms. Our studies showing a 
lack of cross-tolerance between morphine and fentanyl when injected into the vlPAG 
supports the hypothesis that different mechanisms are engaged. The vlPAG plays an 
important role in opioid antinociception and tolerance 1, 29, 45. In addition, the lack of 
cross-tolerance when rats are pretreated with a single opioid(morphine or fentanyl) and 
then given the co-administration also suggests distinct neural mechanisms underlie 
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tolerance to each drug. The important implication of this experiment is that lower doses 
of the opioids can be used for effective antinociception after tolerance has developed to 
a single opioid. However, when both morphine and fentanyl are combined during 
pretreatment and tolerance assessment, we find tolerance does develop, likely because 
both morphine and fentanyl tolerance mechanisms are being activated. An interesting 
finding is that rats pretreated with repeated co-administration of morphine and fentanyl 
produces cross-tolerance to morphine alone, but not fentanyl alone. This may be 
attributed to the half doses that were used in the co-administration pretreatment 
compared to when the drugs were administered alone. It is possible that the dose of 
fentanyl used in the pretreatment is inadequate to induce tolerance, whereas the dose 
used for morphine is sufficient to induce tolerance.  
A potential contributing factor to the lack of cross-tolerance between opioids is that 
the affinity and efficacy at the MOPr differs between agonists. It has been shown that 
MOPr agonists bind and activate different splice variants of the MOPr, which may be 
linked to the ligand-biased effects seen in this study. Fentanyl, but not morphine 
antinociception is blocked following deletion of a particular exon on the MOPr, although 
the MOPr isoforms in the vlPAG have not been identified 34. In addition, the formation of 
heterodimers (e.g., MOPr/DOPr) could contribute to downstream signaling involved in 
tolerance for the different opioids 8.  
Morphine and fentanyl also differ in efficacy. Morphine efficacy is lower than that of 
fentanyl whether assessed with [35S]GTPγS 23, 25, 46 or when assessing the 
antinociceptive effects following systemic or intrathecal administration 22, 30. The 
relationship between efficacy and antinociceptive tolerance is not clear because efficacy 
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correlates with MOPr internalization 12. Efficacy is unlikely to have an effect on the lack 
of cross-tolerance reported here because we have found that morphine and fentanyl 
have equal antinociceptive efficacies when microinjected into the vlPAG 1. 
These initial differences in receptor coupling and regulation may lead to differences 
in activation of signaling cascades and tolerance development. Ligand-biased signaling 
at the MOPr is the most likely explanation for the lack of cross-tolerance between 
morphine and fentanyl 25.  Morphine is typically inferior to fentanyl in inducing MOPr 
phosphorylation, desensitization, and internalization. Fentanyl causes phosphorylation 
of the MOPr via GRK, whereas morphine uses a PKC mediated mechanism 17. In many 
tissue preparations morphine is very weak at inducing MOPr internalization compared to 
other agonists such as fentanyl 6, 7, 25, 26, 48. This functionally selective difference in 
signaling has been shown to alter morphine and fentanyl antinociception. Blockade of 
MOPr internalization with dyn-DN had no effect on morphine antinociception, but 
enhanced fentanyl antinociception 2. In contrast, inhibition of Gαi/o-proteins by pertussis 
toxin (PTX) caused a reduction in morphine, but not fentanyl-induced antinociception 4, 
14, 15. 
Blockade of a component of β-arrestin signaling (i.e. G-protein receptor kinase or 
extracellular signal regulated kinase) has been shown to prevent tolerance to agonists, 
such as fentanyl, and have no effect on tolerance to morphine 2, 16, 21, 26, 32. In contrast, 
inhibition of proteins downstream of G-protein signaling (i.e. protein kinase C or c-Jun n-
terminal kinase) causes a reduction in morphine, but not fentanyl tolerance 16, 26, 32. 
Activation of different signaling cascades would limit the development of cross-tolerance 
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between morphine (G-protein-dependent pathway) and fentanyl (β-arrestin -dependent 
pathway).  
The impact of differences in the duration of action between morphine and fentanyl 
is less clear. Fentanyl produces a rapid (3 min) and short-lived (< 30 min) 
antinociceptive effect compared to morphine microinjection into the vlPAG (peak effects 
of 15-30 min and duration of 1-2 hours) 3. The short antinociceptive effect of fentanyl 
may be caused by rapid internalization, which would limit signaling through G proteins. 
This could explain the lack of cross-tolerance from fentanyl to morphine, but not from 
morphine to fentanyl because prolonged G protein signaling by morphine should cause 
adaptations that affect any MOPr bound ligand. 
A final difference between the two drugs is how they are metabolized. Morphine is 
metabolized into morphine-6-glucurunide or morphine-3-glucurunide, whereas there are 
no known active metabolites of fentanyl 11, 13. The combined MOPr activation of 
morphine and morphine-6-glucurunide may contribute to the development of tolerance. 
Furthermore, morphine-3-glucurunide activation of TLR4 has been recently shown to 
contribute to morphine tolerance within the PAG 11. Once again, this difference may 
contribute to differences in tolerance between morphine and fentanyl, but is unlikely to 
prevent cross-tolerance between these drugs. 
In conclusion, the current study shows a clear lack of cross-tolerance between 
morphine and fentanyl when microinjected into the vlPAG. Although tolerance occurs 
with co-administration of morphine and fentanyl into the vlPAG, cross-tolerance was 
only evident to morphine not fentanyl. The implication of this research is that once 
tolerance develops to a single opioid, co-administration of lower doses of two different 
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opioid can be co-administered to achieve antinociception. These data support clinical 
findings suggesting that co-administration of opioids is more effective than 
administration of a single opioid whether it is morphine or fentanyl. The presence of 
distinct tolerance mechanisms provides new targets for drug development to improve 
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Figure 1. Location of injection sites within the vlPAG. Cannula placements for animals 
pretreated with saline, morphine, fentanyl, or morphine+fentanyl. Injection sites were 
similar for all groups across coronal sections of the PAG. Although the image shows the 
location of the cannula tip, an injection volume of 0.4 µl causes the drug to diffuse into 




Figure 2. Time course for antinociception following vlPAG morphine, fentanyl, and co-
administration of morphine and fentanyl.Microinjection of morphine (5 μg/0.4 μL), 
fentanyl (3 μg/0.4 μL), and combined morphine + fentanyl (2.5 μg + 1.5 μg/0.4 μL) 
showed an increase in hot platency 5 min following vlPAG microinjection.  Hot plate 
latency remained elevated for 90 min following administration of morphine (N = 8-16) or 
morphine and fentanyl (N = 8). In contrast, the increase in hot plate latency caused by 
fentanyl (N = 8-15) administration had returned to near baseline levels within 30 min. 




Figure 3. Lack of cross-tolerance between vlPAG morphine, and fentanyl.  Rats were 
injected twice daily for two days with saline (0.4 μL), morphine (5 μg/0.4 μL), or fentanyl 
(3 μg/0.4 μL) into the vlPAG. (a) The antinociceptive potency of morphine did not differ 
between rats pretreated with fentanyl (N = 8) or saline (N = 8). (b) Likewise, the 
antinociceptive potency of fentanyl did not differ between rats pretreated with morphine 
(N = 7) or saline (N = 8). 
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Figure 4. Co-administration of morphine and fentanyl cause cross-tolerance to morphine 
but not fentanyl. (a) Repeated microinjections of morphine (2.5 μg/0.4 μL) and fentanyl 
(1.5 μg/0.4 μL) into the vlPAG (N = 7) for two days caused a rightward shift in the 
morphine dose response curve compared to saline pretreated rats (N = 7) as would be 
expected with the development of tolerance. (b) In contrast, co-administration of 
morphine and fentanyl (N = 8) had no effect on the fentanyl dose-response curve 





Figure 5. Lack of tolerance to morphine and fentanyl combined following pretreatment 
with morphine or fentanyl alone. (a) Twice daily microinjections of morphine (5 μg/0.4 
μL) or fentanyl (5 μg/0.4 μL) for two days did not cause tolerance to the combination of 
morphine+fentanyl. (b) Twice daily microinjections of morphine+fentanyl for two days 
caused a rightward shift in the combined dose-response. (N = 8/group) 
